Latanogan

Latanoprost, the active ingredient in Latanogan, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension, helping to preserve visual function.

GNH USA supplies Latanogan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets. Our distribution network adheres to stringent quality standards, providing reliable access to essential ophthalmic medicines for eye‑care providers around the globe.

Latanoprost is employed to reduce intra‑ocular pressure in glaucoma‑related conditions.

Primary open‑angle glaucoma: lowers intra‑ocular pressure, helping to preserve visual field and delay disease progression. Secondary open‑angle glaucoma (including pseudoexfoliative): assists in controlling pressure when other therapies are insufficient. Ocular hypertension: reduces pressure to prevent conversion to glaucoma.

Latanoprost may cause ocular and peri‑ocular reactions.

Common Side Effects: - Conjunctival hyperemia: redness of the eye. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation: gradual darkening of eye colour. - Eye irritation or foreign‑body sensation.

Serious or Rare Side Effects: - Uveitis: inflammation inside the eye. - Macular edema: swelling of the central retina. - Severe allergic reaction: swelling, itching, or rash. - Persistent eye pain or vision changes.

Patients should be monitored for ocular health and potential adverse reactions.

Monitor intra‑ocular pressure: schedule regular measurements to assess efficacy. Assess for ocular infections: avoid use if active infection is present. Discontinue contact lens wear: remove lenses during treatment and for at least 15 minutes after instillation. Use with caution in a history of uveitis: increased risk of inflammation. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: may increase local side effects. - Systemic prostaglandin therapy: potential additive effect on intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may affect drug absorption. - Beta‑blocker eye drops: additive IOP‑lowering effect requiring pressure monitoring. - Corticosteroid eye drops: may reduce latanoprost efficacy.